Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
> Conclusion
Abbreviations
Novartis is a focused company playing in an attractive market,
with a differentiated portfolio and strong global footprint
Attractive market
& financials
>$1 tn IM market
Cardiovascular, Immunology,
Neuroscience, Solid Tumors and
Hematology - attractive TAS
+4% sales growth
(2021-2027, % cc, CAGR)
~40%+ core margin (2027+)
Shareholder focused
capital allocation
Differentiated
portfolio
5 core TAS
Emerging leadership with
clear disease area priorities
Strong mid/late-stage
pipeline
Focused on high value innovation
3 next-generation platforms
Leadership across technology platforms
Expanding % IM sales from biologics and
technology platforms
Strong global
footprint
~280 m patients¹
reached in 140 countries
Building US to a top 5 player and
reinforcing international leadership
Leading R&D organization
Industry leading development engine
$9 bn in R&D spend²
>30 manufacturing sites
Incl. leading capabilities in Cell, Gene,
and Radioligand Therapies
1. Including IM + Global Health 2021 2. Core R&D actuals 2021
30
Novartis Investor Presentation | September 22, 2022
U
NOVARTIS | Reimagining MedicineView entire presentation